Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Tuesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 0.9 %

NYSE BTX opened at $1.71 on Tuesday. The firm has a market cap of $100.86 million, a P/E ratio of -0.76 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10. The business’s 50-day moving average price is $1.74 and its 200 day moving average price is $1.97.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.